Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial-Reference-Cited by-同舟云学术

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

Published:2024-03-04 Issue:4 Volume:30 Page:1035-1043
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Wang Feng^ORCID,Jin Ying^ORCID,Wang Min,Luo Hui-Yan^ORCID,Fang Wei-Jia^ORCID,Wang Ying-Nan,Chen Yan-Xing,Huang Run-Jie,Guan Wen-Long,Li Ji-Bin^ORCID,Li Yu-Hong,Wang Feng-Hua,Hu Xiao-Hua,Zhang Yan-Qiao,Qiu Miao-Zhen,Liu Lu-Lu,Wang Zi-Xian,Ren Chao,Wang De-Shen,Zhang Dong-Sheng,Wang Zhi-Qiang,Liao Wen-Ting^ORCID,Tian Lin^ORCID,Zhao Qi^ORCID,Xu Rui-Hua^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-02813-1.pdf

Reference50 articles.

1. Wang, Z.-X. et al. Temporal change in treatment patterns of metastatic colorectal cancer and its association with patient survival: a retrospective cohort study based on an intelligent big-data platform. Engineering 7, 526–533 (2021).

2. Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659–670 (2022).

3. Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J. Clin. Oncol. 40, 161–170 (2022).

4. Chen, G. et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol. Hepatol. 8, 422–431 (2023).

5. Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363–2376 (2022).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies;Biomedicine & Pharmacotherapy;2024-09

3. Integrated bioinformatics analysis and validation identify KIR2DL4 as a novel biomarker for predicting chemotherapy resistance and prognosis in Colorectal Cancer;Heliyon;2024-09

4. Immune Checkpoint Inhibitors in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

5. Obesity-Associated Colorectal Cancer;International Journal of Molecular Sciences;2024-08-14